DALLAS, June 3, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Rexahn Pharmaceuticals Inc. (AMEX:RNN). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: www.microstockprofit.com/lp/RNN
Rexahn Pharmaceuticals Inc. (RNN) is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of treatments for cancer, central nervous system (CNS) disorders, sexual dysfunction and other medical needs. The Company develops therapies that make it possible to regain normalcy for patients suffering from disease. It has three drug candidates in Phase II clinical trials during the year ended December 31, 2008, and six or more other drug candidates in pre-clinical development. The Company's clinical-stage pipeline products include Archexin, an anti-cancer Akt inhibitor; Serdaxin, an antidepressant and CNS Disorders drug; and Zoraxel, an erectile dysfunction (ED) and sexual dysfunction drug. RNN's pre-clinical pipeline includes RX-0201-Nano, RX-0047-Nano, Nano-polymer Anticancer Drugs, RX-0183, RX-5902 and RX-3117.
Message Board Search for RNN: http://www.boardcentral.com/boards/RNN
In the report, the analyst notes:
"For the three-month period ended March 31, 2010, RNN recorded revenues of $18,750. RNN recorded the same amounts in the same period of 2009. In all periods, the revenue reflects the recognition of deferred revenue from a collaborative research agreement with Rexgene Biotech Co. Ltd., a minority stockholder.
"RNN recently announced that it will initiate a phase IIb clinical trial for ZoraxelTM in the treatment of erectile dysfunction (ED). The phase IIb study is designed to assess Zoraxel's efficacy in approximately 225 male subjects, ages 18 to 65, with ED. The double blind, randomized, placebo-controlled, 12-week study will include the International Index of Erectile Function (IIEF), Sexual Encounter Profile (SEP) survey and quality of life study endpoints."
To read the entire report visit: www.microstockprofit.com/lp/RNN
See what investors are saying about RNN at penny stock forum
MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.